ALX Oncology Holdings Statistics
Total Valuation
ALXO has a market cap or net worth of $274.51 million. The enterprise value is $147.23 million.
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, after market close.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALXO has 134.56 million shares outstanding. The number of shares has increased by 25.44% in one year.
| Current Share Class | 134.56M |
| Shares Outstanding | 134.56M |
| Shares Change (YoY) | +25.44% |
| Shares Change (QoQ) | +92.64% |
| Owned by Insiders (%) | 1.23% |
| Owned by Institutions (%) | 37.44% |
| Float | 77.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.81 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.21, with a Debt / Equity ratio of 0.09.
| Current Ratio | 7.21 |
| Quick Ratio | 7.00 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -57.62 |
Financial Efficiency
Return on equity (ROE) is -74.17% and return on invested capital (ROIC) is -40.85%.
| Return on Equity (ROE) | -74.17% |
| Return on Assets (ROA) | -36.76% |
| Return on Invested Capital (ROIC) | -40.85% |
| Return on Capital Employed (ROCE) | -55.64% |
| Weighted Average Cost of Capital (WACC) | 6.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.07M |
| Employee Count | 43 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +345.71% in the last 52 weeks. The beta is 0.45, so ALXO's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +345.71% |
| 50-Day Moving Average | 1.77 |
| 200-Day Moving Average | 1.70 |
| Relative Strength Index (RSI) | 65.95 |
| Average Volume (20 Days) | 1,945,718 |
Short Selling Information
The latest short interest is 2.59 million, so 1.92% of the outstanding shares have been sold short.
| Short Interest | 2.59M |
| Short Previous Month | 1.71M |
| Short % of Shares Out | 1.92% |
| Short % of Float | 3.34% |
| Short Ratio (days to cover) | 2.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -87.99M |
| Pretax Income | -88.87M |
| Net Income | -88.87M |
| EBITDA | -87.35M |
| EBIT | -87.99M |
| Earnings Per Share (EPS) | -$1.34 |
Full Income StatementBalance Sheet
The company has $140.32 million in cash and $13.05 million in debt, giving a net cash position of $127.28 million or $0.95 per share.
| Cash & Cash Equivalents | 140.32M |
| Total Debt | 13.05M |
| Net Cash | 127.28M |
| Net Cash Per Share | $0.95 |
| Equity (Book Value) | 151.35M |
| Book Value Per Share | 1.12 |
| Working Capital | 125.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$78.13 million and capital expenditures -$202,000, giving a free cash flow of -$78.33 million.
| Operating Cash Flow | -78.13M |
| Capital Expenditures | -202,000 |
| Depreciation & Amortization | 645,000 |
| Net Borrowing | -2.67M |
| Free Cash Flow | -78.33M |
| FCF Per Share | -$0.58 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |